SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms SU2C-SARC032
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.
- 11 Jul 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
- 21 Jun 2017 Planned End Date changed from 30 May 2025 to 30 Jul 2025.